MedTrace Logo

Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong

NCT00462202 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2017-03-03

No results posted yet for this study

Summary

The purpose of this study is to assess the tolerability and safety of KRX-101 in treating persistent microalbuminuria in type 2 diabetic patients who are also being treated with stable, maximum tolerated doses of either ACE inhibitors or A2 receptor blockers.

Conditions

  • Diabetic Nephropathy

Interventions

DRUG

sulodexide

Sponsors & Collaborators

  • Collaborative Study Group (CSG)

    collaborator NETWORK

  • Keryx Biopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Robert Atkins, MD · Monash Medical Centre

  • Anne Reutens, MD · Monash Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00462202 on ClinicalTrials.gov